JO
NRSN icon

John Overdeck’s NeuroSense Therapeutics NRSN Stock Holding History

John Overdeck’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-44,445
Closed -$33.6K – 5313
2026
Q1 		$33.6K Sell
44,445
-7,100
-14% -$6.34K ﹤0.01% 4489
2025
Q4 		$39.6K Buy
51,545
+30,459
+144% +$32.1K ﹤0.01% 3957
2025
Q3 		$26.4K Buy
+21,086
New +$30.9K ﹤0.01% 3582

Other funds holding NRSN

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

John Overdeck's NRSN Position: Q2 2026 in Review

John Overdeck sold out of NeuroSense Therapeutics (NRSN) in Q2 2026, closing a stake of 44,445 shares — an estimated $33.6K sold.

John Overdeck first reported a position in NRSN in Q3 2025 and held it in 3 quarters. The position peaked at $39.6K in Q4 2025. 12 funds tracked by Wall St. Rank hold NRSN as of Q2 2026.

  • John Overdeck reported no remaining NeuroSense Therapeutics position as of Q2 2026 after selling out during the quarter.
  • John Overdeck sold 44,445 NeuroSense Therapeutics shares in Q2 2026, an estimated $33.6K.
  • John Overdeck first reported a position in NeuroSense Therapeutics in Q3 2025 and held it in 3 quarters.
  • John Overdeck's NeuroSense Therapeutics position peaked at $39.6K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.